Congress Asset Management Co. Has $153.83 Million Holdings in Boston Scientific Co. (NYSE:BSX)

Congress Asset Management Co. increased its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 0.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,722,192 shares of the medical equipment provider's stock after purchasing an additional 3,538 shares during the period. Boston Scientific accounts for 1.0% of Congress Asset Management Co.'s portfolio, making the stock its 18th largest position. Congress Asset Management Co. owned approximately 0.12% of Boston Scientific worth $153,826,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in the stock. Creative Planning raised its stake in Boston Scientific by 7.7% during the 3rd quarter. Creative Planning now owns 204,208 shares of the medical equipment provider's stock valued at $17,113,000 after acquiring an additional 14,663 shares in the last quarter. Global Retirement Partners LLC raised its stake in Boston Scientific by 11.5% during the 3rd quarter. Global Retirement Partners LLC now owns 4,370 shares of the medical equipment provider's stock valued at $366,000 after acquiring an additional 449 shares in the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd raised its stake in Boston Scientific by 2.0% during the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 172,494 shares of the medical equipment provider's stock valued at $14,455,000 after acquiring an additional 3,433 shares in the last quarter. V Square Quantitative Management LLC raised its stake in Boston Scientific by 20.8% during the 3rd quarter. V Square Quantitative Management LLC now owns 11,133 shares of the medical equipment provider's stock valued at $933,000 after acquiring an additional 1,914 shares in the last quarter. Finally, Stonegate Investment Group LLC raised its stake in Boston Scientific by 7.5% during the 3rd quarter. Stonegate Investment Group LLC now owns 7,701 shares of the medical equipment provider's stock valued at $645,000 after acquiring an additional 534 shares in the last quarter. Institutional investors own 89.07% of the company's stock.

Insider Activity at Boston Scientific

In related news, CFO Daniel J. Brennan sold 67,333 shares of Boston Scientific stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $105.24, for a total transaction of $7,086,124.92. Following the completion of the sale, the chief financial officer now owns 225,808 shares of the company's stock, valued at approximately $23,764,033.92. This trade represents a 22.97 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP John Bradley Sorenson sold 2,657 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $104.41, for a total value of $277,417.37. Following the completion of the sale, the executive vice president now directly owns 24,294 shares of the company's stock, valued at $2,536,536.54. This represents a 9.86 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 158,517 shares of company stock valued at $16,165,168. Insiders own 0.50% of the company's stock.

Analyst Ratings Changes

BSX has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft raised Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 target price on the stock in a research note on Friday, January 10th. Citigroup lifted their target price on Boston Scientific from $107.00 to $122.00 and gave the company a "buy" rating in a research note on Thursday, February 6th. Bank of America lifted their price target on Boston Scientific from $90.00 to $100.00 and gave the company a "buy" rating in a research report on Tuesday, October 22nd. StockNews.com upgraded Boston Scientific from a "hold" rating to a "buy" rating in a research report on Wednesday, January 29th. Finally, JPMorgan Chase & Co. lifted their price target on Boston Scientific from $100.00 to $110.00 and gave the company an "overweight" rating in a research report on Monday, December 16th. One analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Boston Scientific currently has a consensus rating of "Buy" and a consensus target price of $107.39.

Boston Scientific Stock Up 0.3 %

BSX traded up $0.28 during trading on Wednesday, reaching $105.63. 4,304,860 shares of the stock traded hands, compared to its average volume of 6,048,416. The stock has a market cap of $155.68 billion, a price-to-earnings ratio of 84.50, a price-to-earnings-growth ratio of 2.81 and a beta of 0.80. Boston Scientific Co. has a fifty-two week low of $65.33 and a fifty-two week high of $107.17. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. The stock's 50-day simple moving average is $97.09 and its two-hundred day simple moving average is $88.82.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 18.11% and a net margin of 11.07%. As a group, equities research analysts expect that Boston Scientific Co. will post 2.85 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.